Departing Novo chief wins ‘best CEO’ nod again, and Biogen’s grabs laurels, too

Departing Novo chief wins ‘best CEO’ nod again, and Biogen’s grabs laurels, too

n its annual list of the world’s 100 top CEOs, Harvard Business Review tagged 5 biopharma execs–and one, Novo Nordisk CEO Lars Rebien Sørensen, took the No. 1 slot for the second year in a row. Thing is, two of those 5 are on their way out.

That includes Sørensen, who’s stepping down early, yielding his spot to Lars Fruergaard Jorgensen at the end of this year. And Biogen chief George Scangos, who clocked in at 21st place on HBR’s ranking, has also said he’ll step down, with a replacement yet to be named.

HBR analyzes long-term CEO performance, measuring returns, sustainability and governance over their entire tenure at the helm. In addition to Sørensen and Scangos, the ranking includes Actelion chief Jean-Paul Clozel (59th), Regeneron CEO Leonard Schleifer (67th) and Eisai helmsman Haruo Naito (87th).

Sørensen has presided over an era of growth and returns at Novo that has far outstripped the industry, and that’s one of the reasons why HBR selected him to lead the list again. But the company’s shares plummeted 20% this summer on worries about payer pressure and pricing. And asHBR spokeswoman Amy Poftak wrote in an email, Sørensen’s departure two years before the end of his contract is “a stark reminder that even spectacular past performance doesn’t ensure job security.”

To be fair, Sørensen had intended to step down before the end of his contract, but his presumed successor, Kåre Schultz, jumped ship last year to serve as CEO at fellow Danish drugmaker Lundbeck. Meanwhile, pressure on the diabetes-focused Novo was intensifying, so Sørensen agreed to stick around to help navigate.

Indeed, a diabetes market that turned rocky almost overnight has threatened Novo in a way it hasn’t seen before. Payer pressure on the company’s newest launches–in the U.S., its biggest market–has dampened expectations. A biosimilar basal insulin jeopardizes its contender, Levemir, and more importantly, the longer-acting product Tresiba. Stepped-up competition for its blockbuster GLP-1 drug Victoza only adds to the strain.

Sørensen’s decision to retire followed a management restructuring earlier this year designed to emphasize Novo’s international operations and bring several managers into the executive committee to help inform succession planning. The company considered external candidates but decided it was best to tap a CEO already steeped in the “Novo Nordisk Way” and its triple-bottom-line approach.

When Sørensen said he’d stay to help out after Schultz’s departure, the company was facing an “unprecedented number” of new launches, the CEO said during a call with analysts after the announcement that he was leaving. He said the time was now right for a change.

“I think the immediate challenge in the U.S. market has been dealt with,” Sørensen said at the time. “There’s a new group of launches taking place as we speak. … So that will, of course, give a new set of launch challenges, which I think the new management team will be well-equipped to take care of.”

Meanwhile, Biogen has suffered its own declines recently, as its fast-launching multiple sclerosis pill Tecfidera ran into safety concerns, prompting a pullback in prescription growth. As Tecfidera began to flag and shares suffered, the company announced it would cut 11% of its workforce and pull out of some research programs.

Some analysts figure the company needs to make some deals or risk becoming a takeover target itself. Since the cutbacks announcement last October, Biogen has said it would spin off its hemophilia business, which could bring in $5.9 billion in cash to play with. The company’s Q2 results were solid. But the new CEO, whoever that happens to be, will have plenty of challenges ahead.


Our Facebook page Comments


We are proud to announce that MEDLINES – Healthcare headlines started its’ very own blog site. Our mission is to bring the very best of the news and newsworthy issues of the medical field, from university news to business and tech info.

Leave a Reply